Screener
Sutro Biopharma STRO Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $9.84M-84.6% | $14.52M-16.5% | $11.65M-21.4% | $9.69M+13.8% | $63.75M+148% | ||
| $31.7M-17.3% | $36.55M-29.2% | $36.64M-48.4% | $39.85M-35.8% | $38.33M-38.2% | ||
| $7.83M-24.3% | $7.58M-42.9% | $8.66M-4.1% | $8.74M-39.0% | $10.34M-16.4% | ||
| $39.73M-40.8% | $44.18M-48.6% | $49.7M-37.9% | $58.15M-23.9% | $67.09M-9.8% | ||
| -$29.89M-794% | -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | -$3.35M+93.1% | ||
| -303.8%-299pp | -204.2%+190pp | -326.7%+114pp | -499.9%+297pp | -5.2%+184pp | ||
| -$38.53M-235% | -$38.5M+49.3% | -$46.84M+33.2% | -$56.86M-16.5% | -$11.52M+76.0% | ||
| $1K+106% | -$15K-314% | -$82K-103% | $0— | -$18K-325% | ||
| -$38.53M-235% | -$38.48M+49.3% | -$46.76M+35.4% | -$56.86M-16.5% | -$11.5M+76.1% | ||
| -391.6%-374pp | -265%+172pp | -401.5%+87.7pp | -586.6%-14.0pp | -18%+169pp | ||
| -$2.33-72.6% | -$2.94+67.6% | -$20.78+24.0% | -$0.67-13.6% | -$1.35-129% | ||
| -$28.63M-1,881% | -$28.38M+57.4% | -$36.43M+42.5% | -$46.56M+29.6% | -$1.45M+96.9% | ||
| -290.9%-289pp | -195.4%+187pp | -312.7%+115pp | -480.3%+296pp | -2.3%+180pp | ||
| -$29.89M-794% | -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | -$3.35M+93.1% |
FAQ
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $45.7M in revenue over the trailing twelve months, down 56.3% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $180.6M over the trailing twelve months, a -395.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-26.72.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
